Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated January 18, 2023, serves as a transaction notification for the month of January 2023. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific share transactions executed on January 17, 2023, on the London Stock Exchange (XLON).
| Transaction Type | Instrument | Price (GBP) | Total Volume (Shares) |
|---|---|---|---|
| Acquisition via Dividend Reinvestment | Ordinary Shares (31 1/2 pence each) | 14.3637 | 13,943.648 |
Note: Total volume is the sum of individual transactions listed in the filing.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents routine compliance disclosures regarding insider shareholdings.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed following the dividend payment date of January 12, 2023.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend reinvestment, not open market purchases or sales.
- Participants: Transactions involved 11 individuals, including the CEO (Ms. E. Walmsley), Chief People Officer (Ms. D. Conrad), and other senior executives.
- Execution Details: All trades occurred on January 17, 2023, at a uniform price of £14.3637 per share.
- Scope: This document is a regulatory notification of insider holdings and does not contain financial performance data.